File No. CT/48/21-DCG(I)

GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan
ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

सत्यमेव जयते

File No. CT/21/0000/53

To,

M/s. Novo Nordisk India Pvt Ltd.,
Plot No.32, 47-50, EPIP Area, Whitefield,
Bangalore, Karnataka (India) – 560066.

Sir,

With reference to your application No. GCT/CT04/FF/2021/25698 (GCT/48/21) dated 13-05-2021, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, "**Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial", Protocol Number: NN9500-4656 Version No. 1 dated 06-JAN-2021** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

(i) The firm should include more sites from different zones across the India.

(ii) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;

(iii) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iv) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(v) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(vi) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(vii) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(viii) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(ix) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;

(x) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(xi) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;

(xii) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiii) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiv) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xv) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xvi) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xvii) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xviii) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xix) Merely granting permission to conduct the clinical trial with the Investigational Drug Product does not convey or imply that, based on the clinical trial study data generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;

File No. CT/48/21-DCG(I)

(xx) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

VENUGOPAL GIRDHARILAL SOMANI

Digitally signed by VENUGOPAL GIRDHARILAL SOMANI
DN: c=IN, o=MINISTRY OF HOME AFFAIRS, ou=CDSCO DGHS, postalCode=431401, st=Maharashtra, 2.5.4.20=173d03345df62d489632379a1471bfdae9f0b2bea56c83bfbbe2154e399b1af7, cn=VENUGOPAL GIRDHARILAL SOMANI
Date: 2021.10.26 18:02:50 +05'30'

(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licencing Authority
Stamp

File No. CT/48/21-DCG(I)

FORM CT-06

(See rules 22,25,26,29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

1. The Central Licensing Authority hereby permits **M/s. Novo Nordisk India Pvt. Ltd., Plot No. 32, 47 - 50, EPIP Area, Whitefield Bangalore (India) - 560066** to conduct clinical trial of the new drug or investigational new drug as per **Protocol Number: NN9500-4656 Version No. 1 dated 06-JAN-2021** in the below mentioned clinical trial sites [As per Annexure].-

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date _____

VENUGOPAL GIRDHARILAL SOMANI

Digitally signed by VENUGOPAL GIRDHARILAL SOMANI
DN: c=IN, o=MINISTRY OF HOME AFFAIRS, ou=CDSCO DGHS, postalCode=431401, st=Maharashtra, 2.5.4.20=173d03345df62d489632379a1471bfdae9f0b2bea56c83bfbbe2154e399b1af7, cn=VENUGOPAL GIRDHARILAL SOMANI
Date: 2021.10.26 18:03:02 +05'30'

(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licencing Authority
Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	1. NNC0194-0449 B 50 mg/ml 2. Semaglutide 3mg/ml 3. NNC0174-0833 A 10 mg/ml
Therapeutic class:	Non alcoholic steatohepatitis
Dosage form:	Solution for injection
Composition:	Sodium hydroxide = 1.0000 q.s. U.S.P., J.P., Ph. Eur Inactive NNC0194-0499 = 50.0000 milligram (mg) In House Specification Active Glycerol = 20.0000 milligram (mg) U.S.P., J.P., Ph. Eur Inactive Water for injection = 1.0000 To 1 ml U.S.P., J.P., Ph. Eur Inactive Sodium dihydrogen phosphate dihydrate = 0.0700 milligram (mg) U.S.P., Ph. Eur Inactive Hydrochloric acid = 1.0000 q.s. U.S.P., J.P., Ph. Eur Inactive Disodium hydrogen phosphate dihydrate = 1.7000 milligram (mg) U.S.P., Ph. Eur Inactive

	Propylene glycol = 14.0000 milligram (mg) U.S.P., J.P., Ph. Eur Inactive Semaglutide = 3.0000 milligram (mg) In House Specification Active Water for injection = 1.0000 To 1 ml U.S.P.,J .P., Ph. Eur Inactive Hydrochloric acid = 1.0000 q.s. U.S.P., J.P., Ph. Eur Inactive Disodium hydrogen phosphate, dihydrate =1.4200 milligram (mg) U.S.P., Ph. Eur Inactive Sodium hydroxide = 1.0000 q.s. U.S.P., J.P., Ph. Eur Inactive Phenol = 5.5000 milligram (mg) U.S.P.,J .P., Ph. Eur Inactive Glycerol = 23.0000 milligram (mg) U.S.P., J.P., Ph. Eur Inactive Hydrochloric acid = 1.0000 q.s. U.S.P., J.P., Ph. Eur Inactive Water for injection = 1.0000 To 1 ml U.S.P., J.P., Ph. Eur Inactive Sodium acetate, trihydrate = 0.6800 milligram (mg) U.S.P., J.P., Ph. Eur Inactive m-Cresol = 2.1600 milligram (mg) U.S.P., Ph. Eur Inactive Sodium hydroxide = 1.0000 q.s. U.S.P., J.P., Ph.Eur Inactive NNC0174-0833 = 10.0000 milligram (mg) In House Specification Active
Indications:	Non alcoholic steatohepatitis (NASH)

Annexure:

Details of clinical trial site:

Sr. No.	**Names and address of clinical trial site**	**Ethics committee details**	**Name of investigator**
1.	Department of Hepatology, Nehru Hospital Extension Block (NHE), Ground floor, room no.32 Post Graduate institute of Medical education and Research (PGIMER) Chandigarh-160012	Institutional Ethics Committee, Research B block PGIMER Chandigarh – 160012 ECR/25/Inst/CH/2013/RR-20	Dr. Ajay Duseja
2.	Kalla Mukesh S.R. Kalla Memorial Gastro & General Hospital, 78-79 Dhuleshwar Garden Behind HSETC Bank Sardar Patel Marg C-scheme Jaipur-302001, Rajasthan India	S.R. Kalla Memorial Ethical Committee For Human Research, S.R. Kalla Memorial Gastro & General Hospital, 78-79 Dhuleshwar Garden Behind HSI3C Bank, Sardar Patel Marg C-Scheme Jaipur-302001, Rajasthan, India ECR/8/Inst/Raj/2013/RR-19	Dr. Kalla Mukesh
3.	Surat Institute of Digestive Sciences Vijay Nagar Gate no. 3, Besides Nirman Bhavan, Opposite Gandhi College, 395002, Surat, Gujarat, India	Surat Institute of Digestive Sciences, Surat Institute of Digestive Sciences, A unit of SIDS Healthcare Pvt. Ltd., JJ Empire, Vijay Nagar-3, Besides Nirman Bhavan, Majura Gate Surat, Gujarat 395002, India ECR/813/Inst/GJ/2016/RR-19	Dr. Rajiv Manhar Mehta

File No. CT/48/21-DCG(I)

4.	Global Hospital-Super Speciality and transplant Centre (A unit of Centre for Digestive and Kidney Disease) (India) Pvt. Ltd., 35, Dr. E. Borges Road, Hospital Avenue, Opp. Shirodkar High School, Parel, Mumbai-400012, Maharashtra, India	Institutional Ethics Committee Room No. 306 B, 3 Floor, Maulana Azad Medical College, New Delhi-02 ECR/493/Inst/MH/2014/RR-19	Dr. Shah Samir Ramnik
5.	Department of Gastroenterology, Kasturba Medical College (KMC) Hospital, Dr. B R Ambedkar Circle, Mangalore-575001, Karnataka, India	Manipal Academy of Higher Education (MAHE) Ethics Committee, Mezzanine Floor, KMC Old Library Building, Madhava Nagar, Manipal-576104 ECR/191/Inst/KL/2013/RR-19	Dr. Tantry B Vishwanath
6.	Seth GS Medical College & KEM Hospital, Department of Gastroenterology, Ward 32A,9th Floor, M S Building, Parel, Mumbai-400012	Institutional Ethics Committee (IEC) 1 & 2, New UG-PG Hostel, 20 Storey Hostel Building, Ground Floor, Seth GS Medical College & KEM Hospital, Parel, Mumbai-400012 ECR/229/Inst/MH/2013/RR-19	Dr. Akash Shukla
7.	Midas Multispeciality Hospital Pvt. Ltd., Midas Heights, 07, Central Bazar Road, Ramdas Peth, Nagpur-440010, Maharashtra	Institutional Ethics Committee, Midas Multispeciality Hospital Pvt. Ltd., Midas Heights, 07, Central Bazar Road, Ramdas Peth, Nagpur-440010, Maharashtra ECR/494/inst/mh/2014/rr-20	Dr. Shrikant Mukewar
8.	Department of Gastroenterology, SMS Hospital, J.L.N. Marg, Jaipur-302004	S.M.S. Medical College and attached Hospitals, Jaipur, Office of Ethics Committee, Second Floor, New Academic Block, S.M.S. Medical College, J.L.N. Marg, Jaipur-302004, Rajasthan, India ECR/26/Inst/RJ/2013/RR-19	Dr. Gaurav Kumar Gupta
9.	Institute of Billiary Sciences, D-1 Vasant Kunj, New Delhi-110070, India	Institutional Ethics Committee, ILBS, D-1 Vasant Kunj, New Delhi-110070, India ECR/67/inst/dl/2013/rr-19	Dr. Shiv Kumar Sarin
10.	All India Institute of Medical Sciences, Ansari Nagar, New Delhi	The Institute of Ethics Committee, Room no. 102, First Floor, Old OT Block, All India Institute of Medical Sciences, Ansari Nagar, New Delhi ECR/538/inst/dl/2014/rr-20	Dr. Shalimar

File No. CT/48/21-DCG(I)

11.	Yashoda Hospitals, Secunderabad, Hyderabad, Telangana- 500003	Institutional-Ethics Committee, Yashoda Academy of Medical Education and Research, Yashoda Hospitals, Behind Hari Hara Kalabhavan, Alexander Road Secunderabad. Hyderabad, Telanagana – 500003 ECR/49/Inst/AP/2013/RR-19	Dr. Dharmesh Kapoor
12.	Dayanand Medical College & Hospital, Tagore Nagar, Civil Lines, Ludhiana-141001, Punjab, India	Drug Trial Ethics Committee, Dayanand Medical College & Hospital, Tagore Nagar, Civil Lines, Ludhiana-141001, Punjab, India ECR/101/Inst/PB/2013/RR-19	Dr. Vandana Midha